Compare Inovio Pharmaceuticals Inc (INO) vs SiTime Corporation (SITM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs SiTime Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while SiTime Corporation trades at $695.84 (market cap $20.05B). The key difference: SiTime Corporation is far larger — about 255.3× Inovio Pharmaceuticals Inc's market cap, and SiTime Corporation is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SITM | |
|---|---|---|
Market Cap | $78.55M | $20.05B |
Sector | Health | Technology |
52-Week High | $2.87 | $901.60 |
52-Week Low | $0.66 | $212.77 |
Enterprise Value | $49.56M | $19.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
SiTime Corporation (SITM) trades at $697.50, up 1.09% with strong bullish technical signals and consistent earnings beats. The stock shows robust revenue growth, expanding margins, and positive analyst sentiment with a $870 consensus price target. Recent Q2 2026 results exceeded expectations with 127% revenue growth, driven by AI infrastructure demand and the Renesas acquisition.
Outlook remains positive with AI timing growth as the key catalyst, though premium valuation and integration risks warrant caution. The stock offers significant upside potential from current levels but faces execution risks in scaling operations and maintaining margin expansion amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →
